The CDC has published guidance recommending that providers counsel certain patients on the harms and benefits of doxycycline for post-exposure prophylaxis — or doxy-PEP — for the prevention of sexually transmitted infections.
The recommendations are based on promising evidence showing that doxy-PEP is effective at preventing STIs.
“No vaccines and few chemoprophylaxis options exist for the prevention of bacterial STIs (specifically syphilis, chlamydia, and gonorrhea),” Laura H. Bachmann, MD, chief medical officer of the Division of STD Prevention at the CDC’s